Zardaverine

Zardaverine
Names
	Preferred IUPAC name 6-[3-(Difluoromethoxy)-4-methoxyphenyl]pyridazin-3(2H)-one
Identifiers
CAS Number	101975-10-4 ;
3D model (JSmol)	Interactive image;
ChemSpider	5521;
PubChem CID	5723;
UNII	TQ358GWH6Y ;
CompTox Dashboard (EPA)	DTXSID8042559 ;
	InChI InChI=1S/C12H10F2N2O3/c1-18-10-6-7(2-4-9(10)19-12(13)14)8-3-5-11(17)16-15-8/h2-6,12H,1H3,(H,16,17) Key: HJMQDJPMQIHLPB-UHFFFAOYSA-N;
	SMILES COC1=C(C=CC(=C1)C2=NNC(=O)C=C2)OC(F)F;
Properties
Chemical formula	C12H10F2N2O3
Molar mass	268.220 g·mol−1
	Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). Infobox references

Zardaverine is a dual-selective PDE3/4 phosphodiesterase inhibitor.^[1] Studies in vitro suggest that it may have useful anti-cancer properties.^[2]

References

^ Kümmerle, AE; Schmitt, M; Cardozo, SV; Lugnier, C; Villa, P; Lopes, AB; Romeiro, NC; Justiniano, H; Martins, MA; Fraga, CA; Bourguignon, JJ; Barreiro, EJ (2012). "Design, Synthesis, and Pharmacological Evaluation of N-Acylhydrazones and Novel Conformationally Constrained Compounds as Selective and Potent Orally Active Phosphodiesterase-4 Inhibitors". Journal of Medicinal Chemistry. 55 (17): 7525–45. doi:10.1021/jm300514y. PMID 22891752.
^ Corsello SM, Nagari RT, Spangler RD, et al. Discovering the anticancer potential of non-oncology drugs by systematic viability profiling. Nature Cancer (2020). doi:10.1038/s43018-019-0018-6

This article about an organic compound is a stub. You can help Wikipedia by expanding it.

[1] Kümmerle, AE; Schmitt, M; Cardozo, SV; Lugnier, C; Villa, P; Lopes, AB; Romeiro, NC; Justiniano, H; Martins, MA; Fraga, CA; Bourguignon, JJ; Barreiro, EJ (2012). "Design, Synthesis, and Pharmacological Evaluation of N-Acylhydrazones and Novel Conformationally Constrained Compounds as Selective and Potent Orally Active Phosphodiesterase-4 Inhibitors". Journal of Medicinal Chemistry. 55 (17): 7525–45. doi:10.1021/jm300514y. PMID 22891752.

[2] Corsello SM, Nagari RT, Spangler RD, et al. Discovering the anticancer potential of non-oncology drugs by systematic viability profiling. Nature Cancer (2020). doi:10.1038/s43018-019-0018-6

[1]

[2]